Cervical cancer (recurrent) - topotecan (TA183)
Topotecan in combination with cisplatin is recommended as a possible treatment for women with recurrent or stage IVB cervical cancer only if they have not received cisplatin before. Healthcare professionals should not stop prescribing topotecan for women who have received cisplatin before and who were already taking topotecan with cisplatin when the guidance was issued. These women should be able to carry on taking topotecan until they and their healthcare professionals decide that it is the right time to stop treatment.
This page was last updated: 27 November 2012
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA183 Topotecan ar gyfer canser serfigol sy'n dychwelyd a cham IVB: deall canllawiau NICE (fformat MS Word)
Information for the public
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.